Efficacy of sunitinib in patients with metastatic or
unresectable renal cell carcinoma and renal insufficiency

J 2015

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency

POPRACH, Alexandr, Zbyněk BORTLÍČEK, Bohuslav MELICHAR, Radek LAKOMÝ, Marek SVOBODA et. al.

Basic information

Original name

Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency

Authors

POPRACH, Alexandr (203 Czech Republic, belonging to the institution), Zbyněk BORTLÍČEK (203 Czech Republic, guarantor, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution), Igor KISS (203 Czech Republic, belonging to the institution), Milada ZEMANOVA (203 Czech Republic), Ondrej FIALA (203 Czech Republic), Katerina KUBACKOVA (203 Czech Republic), Oldřich COUFAL (203 Czech Republic, belonging to the institution), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Rostislav VYZULA (203 Czech Republic, belonging to the institution) and Tomas BUCHLER (203 Czech Republic)

Edition

European Journal of Cancer, Oxford, Elsevier Science Inc. 2015, 0959-8049

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 6.163

RIV identification code

RIV/00216224:14110/15:00083158

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.ejca.2014.12.010

UT WoS

000350915600008

Keywords in English

Renal insufficiency; Renal cell carcinoma; Sunitinib; Survival; Treatment duration

Abstract

V originále

Aim: The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI). Methods: The cohort included 790 patients treated with sunitinib between 2006 and 2013. At the start of sunitinib therapy 22, 234, and 534 patients had severe (glomerular filtration rate [GFR] <30 ml/min/1.73 m(2)), moderate (GFR 30-60 ml/min/1.73 m(2)) or mild RI/normal renal function (GFR >60 ml/min/1.73 m(2)), respectively. Results: For the three groups defined above, median progression-free survival (PFS) (95% confidence interval [CI]) was 5.3 months (0.1-18.5), 8.1 months (6.2-9.9) and 11.3 months (9.4-13.2) (p = 0.244), and median overall survival (OS) was 26.3 months (1.2-51.4), 21.2 months (13.2-29.1) and 26.3 months (22.6-29.9) (p = 0.443), respectively. The disease control rates were 45.5%, 56.4% and 59.2%, respectively (p = 0.374). No unexpected toxicity was reported in the patients with RI, but the treatment was more frequently discontinued because of adverse events and the duration of therapy was significantly shorter in these patients (p = 0.007). Conclusions: Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.

Citovat

POPRACH, Alexandr, Zbyněk BORTLÍČEK, Bohuslav MELICHAR, Radek LAKOMÝ, Marek SVOBODA, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Katerina KUBACKOVA, Oldřich COUFAL, Tomáš PAVLÍK, Ladislav DUŠEK, Rostislav VYZULA and Tomas BUCHLER. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. European Journal of Cancer. Oxford: Elsevier Science Inc., 2015, vol. 51, No 4, p. 507-513. ISSN 0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2014.12.010.

@article{1301193,
   author = {Poprach, Alexandr and Bortlíček, Zbyněk and Melichar, Bohuslav and Lakomý, Radek and Svoboda, Marek and Kiss, Igor and Zemanova, Milada and Fiala, Ondrej and Kubackova, Katerina and Coufal, Oldřich and Pavlík, Tomáš and Dušek, Ladislav and Vyzula, Rostislav and Buchler, Tomas},
   article_location = {Oxford},
   article_number = {4},
   doi = {http://dx.doi.org/10.1016/j.ejca.2014.12.010},
   keywords = {Renal insufficiency; Renal cell carcinoma; Sunitinib; Survival; Treatment duration},
   language = {eng},
   issn = {0959-8049},
   journal = {European Journal of Cancer},
   title = {Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency},
   volume = {51},
   year = {2015}
}

TY  - JOUR
ID  - 1301193
AU  - Poprach, Alexandr - Bortlíček, Zbyněk - Melichar, Bohuslav - Lakomý, Radek - Svoboda, Marek - Kiss, Igor - Zemanova, Milada - Fiala, Ondrej - Kubackova, Katerina - Coufal, Oldřich - Pavlík, Tomáš - Dušek, Ladislav - Vyzula, Rostislav - Buchler, Tomas
PY  - 2015
TI  - Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency
JF  - European Journal of Cancer
VL  - 51
IS  - 4
SP  - 507-513
EP  - 507-513
PB  - Elsevier Science Inc.
SN  - 09598049
KW  - Renal insufficiency
KW  - Renal cell carcinoma
KW  - Sunitinib
KW  - Survival
KW  - Treatment duration
N2  - Aim: The aim of this retrospective, registry-based study was to analyse treatment outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib and renal insufficiency (RI). Methods: The cohort included 790 patients treated with sunitinib between 2006 and 2013. At the start of sunitinib therapy 22, 234, and 534 patients had severe (glomerular filtration rate [GFR] <30 ml/min/1.73 m(2)), moderate (GFR 30-60 ml/min/1.73 m(2)) or mild RI/normal renal function (GFR >60 ml/min/1.73 m(2)), respectively. Results: For the three groups defined above, median progression-free survival (PFS) (95% confidence interval [CI]) was 5.3 months (0.1-18.5), 8.1 months (6.2-9.9) and 11.3 months (9.4-13.2) (p = 0.244), and median overall survival (OS) was 26.3 months (1.2-51.4), 21.2 months (13.2-29.1) and 26.3 months (22.6-29.9) (p = 0.443), respectively. The disease control rates were 45.5%, 56.4% and 59.2%, respectively (p = 0.374). No unexpected toxicity was reported in the patients with RI, but the treatment was more frequently discontinued because of adverse events and the duration of therapy was significantly shorter in these patients (p = 0.007). Conclusions: Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.
ER  -

POPRACH, Alexandr, Zbyněk BORTLÍČEK, Bohuslav MELICHAR, Radek LAKOMÝ, Marek SVOBODA, Igor KISS, Milada ZEMANOVA, Ondrej FIALA, Katerina KUBACKOVA, Oldřich COUFAL, Tomáš PAVLÍK, Ladislav DUŠEK, Rostislav VYZULA and Tomas BUCHLER. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. \textit{European Journal of Cancer}. Oxford: Elsevier Science Inc., 2015, vol.~51, No~4, p.~507-513. ISSN~0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2014.12.010.

Detailed Information on Publication Record